TISSUE Regenix, which grows replacement body parts, has expanded its agreement with the NHS Blood and Transplant (NHSBT) to develop devices from human tissue.
The new agreement will extend the scope of Tissue Regenix’s clinical development of decellularised human tissue-based devices.
The York-based firm said it will allow for a “significantly expanded” range of products to be developed with the NHSBT. Initially, its work will look at human skin and cardiology.
The company’s unique technology strips human or animal tissue of its DNA, creating a “decellularised” scaffold. This is classed as medical device and can be inserted into a patient to regenerate a body part.
Tissue managing director Antony Odell said: “The new agreement will enable us to fast-track the development of additional applications for our dCELL Dermis products.
“NHSBT has unparalleled relationships with the NHS clinical community and world-class development facilities and these will enable us to jointly address a range of significant clinical needs in a cost and time efficient manner”.
Tissue will retain exclusive rights to commercialise any data generated from the trials. The expanded agreement will allow Tissue to speed up evaluation of other human tissue-based devices.
Head of Tissue Services at NHSBT, Helen Gillan, said: “We welcome the expansion of our partnership with Tissue Regenix. In a rapidly advancing field, we have the specialist facilities and the necessary high-level scientific experience needed to deliver novel patient therapies.”